Bristol Myers Squibb (BMY) Competitors

$55.62 -0.54 (-0.97%)

Closing price 03:59 PM Eastern

Extended Trading

$55.67 +0.06 (+0.10%)

As of 05:05 PM Eastern

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

Should you be buying Bristol Myers Squibb stock or one of its competitors? The main competitors of Bristol Myers Squibb include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV). These companies are all part of the "medical" sector.

How does Bristol Myers Squibb compare to Amgen?

Amgen (NASDAQ:AMGN) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Amgen has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Bristol Myers Squibb has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

Amgen has higher earnings, but lower revenue than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$37.22B	4.78	$7.71B	$14.37	22.94
Bristol Myers Squibb	$48.19B	2.36	$7.05B	$3.56	15.62

76.5% of Amgen shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Amgen currently has a consensus price target of $357.12, indicating a potential upside of 8.35%. Bristol Myers Squibb has a consensus price target of $61.31, indicating a potential upside of 10.24%. Given Bristol Myers Squibb's higher probable upside, analysts plainly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.1%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.5%. Amgen pays out 70.1% of its earnings in the form of a dividend. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years and Bristol Myers Squibb has raised its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a net margin of 20.96% compared to Bristol Myers Squibb's net margin of 15.01%. Amgen's return on equity of 137.41% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Bristol Myers Squibb	15.01%	64.87%	13.16%

In the previous week, Amgen had 1 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 44 mentions for Amgen and 43 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.06 beat Amgen's score of 0.89 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	27 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	31 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

Amgen beats Bristol Myers Squibb on 15 of the 20 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Exelixis?

Bristol Myers Squibb (NYSE:BMY) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Bristol Myers Squibb currently has a consensus price target of $61.31, indicating a potential upside of 10.24%. Exelixis has a consensus price target of $47.83, indicating a potential downside of 3.78%. Given Bristol Myers Squibb's higher possible upside, equities analysts clearly believe Bristol Myers Squibb is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39

In the previous week, Exelixis had 7 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 50 mentions for Exelixis and 43 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.06 beat Exelixis' score of 0.65 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	31 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive
Exelixis	17 Very Positive mention(s)	9 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.08% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
Exelixis	35.08%	39.89%	30.23%

Bristol Myers Squibb has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.

Bristol Myers Squibb has higher revenue and earnings than Exelixis. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.36	$7.05B	$3.56	15.62
Exelixis	$2.38B	5.26	$782.57M	$3.01	16.51

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Exelixis beats Bristol Myers Squibb on 11 of the 17 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Gilead Sciences?

Bristol Myers Squibb (NYSE:BMY) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bristol Myers Squibb has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

In the previous week, Gilead Sciences had 30 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 73 mentions for Gilead Sciences and 43 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.06 beat Gilead Sciences' score of 0.68 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	31 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive
Gilead Sciences	31 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	12 Negative mention(s)	3 Very Negative mention(s)	Positive

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.5%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb currently has a consensus price target of $61.31, indicating a potential upside of 10.24%. Gilead Sciences has a consensus price target of $157.04, indicating a potential upside of 17.61%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.86

Gilead Sciences has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.36	$7.05B	$3.56	15.62
Gilead Sciences	$29.74B	5.57	$8.51B	$7.34	18.19

Gilead Sciences has a net margin of 30.99% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
Gilead Sciences	30.99%	48.19%	18.28%

Summary

Gilead Sciences beats Bristol Myers Squibb on 14 of the 19 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Bristol Myers Squibb (NYSE:BMY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bristol Myers Squibb has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.

In the previous week, Vertex Pharmaceuticals had 10 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 53 mentions for Vertex Pharmaceuticals and 43 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.06 beat Vertex Pharmaceuticals' score of 0.88 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	31 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	28 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Bristol Myers Squibb presently has a consensus price target of $61.31, suggesting a potential upside of 10.24%. Vertex Pharmaceuticals has a consensus price target of $555.17, suggesting a potential upside of 27.58%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37
Vertex Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.85

Bristol Myers Squibb has higher revenue and earnings than Vertex Pharmaceuticals. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.36	$7.05B	$3.56	15.62
Vertex Pharmaceuticals	$12.00B	9.20	$3.95B	$16.86	25.81

Vertex Pharmaceuticals has a net margin of 35.51% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Summary

Vertex Pharmaceuticals beats Bristol Myers Squibb on 13 of the 17 factors compared between the two stocks.

How does Bristol Myers Squibb compare to AbbVie?

Bristol Myers Squibb (NYSE:BMY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

In the previous week, AbbVie had 17 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 60 mentions for AbbVie and 43 mentions for Bristol Myers Squibb. AbbVie's average media sentiment score of 1.16 beat Bristol Myers Squibb's score of 1.06 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	31 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive
AbbVie	42 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Bristol Myers Squibb has higher earnings, but lower revenue than AbbVie. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.36	$7.05B	$3.56	15.62
AbbVie	$62.82B	5.71	$4.23B	$2.03	99.91

Bristol Myers Squibb has a net margin of 15.01% compared to AbbVie's net margin of 5.79%. Bristol Myers Squibb's return on equity of 64.87% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
AbbVie	5.79%	-911.57%	13.43%

Bristol Myers Squibb has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.

Bristol Myers Squibb presently has a consensus price target of $61.31, suggesting a potential upside of 10.24%. AbbVie has a consensus price target of $252.90, suggesting a potential upside of 24.70%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe AbbVie is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.5%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb has increased its dividend for 17 consecutive years and AbbVie has increased its dividend for 53 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

AbbVie beats Bristol Myers Squibb on 13 of the 20 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMY vs. The Competition

Export

Metric	Bristol Myers Squibb	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$113.58B	$3.37B	$6.18B	$22.92B
Dividend Yield	4.49%	2.24%	2.78%	4.02%
P/E Ratio	15.62	15.19	20.66	28.93
Price / Sales	2.36	194.53	527.64	24.53
Price / Cash	6.91	56.93	27.81	19.21
Price / Book	6.12	6.94	9.77	4.65
Net Income	$7.05B	$24.11M	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.20%
1 Month Performance	-5.10%	4.63%	6.28%	3.95%
1 Year Performance	19.92%	78.21%	41.81%	28.96%

Bristol Myers Squibb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMY Bristol Myers Squibb	4.686 of 5 stars	$55.62 -1.0%	$61.31 +10.2%	+21.0%	$113.58B	$48.19B	15.62	32,500	Positive News Analyst Revision
AMGN Amgen	4.3839 of 5 stars	$328.91 -0.7%	$357.12 +8.6%	+24.8%	$178.70B	$37.22B	22.89	31,500	Analyst Revision
EXEL Exelixis	3.0405 of 5 stars	$46.21 -5.1%	$47.83 +3.5%	+33.1%	$12.24B	$2.32B	15.35	1,077	Earnings Report Analyst Upgrade Insider Trade
GILD Gilead Sciences	4.6651 of 5 stars	$134.06 -1.6%	$157.35 +17.4%	+35.6%	$169.18B	$29.44B	19.80	17,000	Earnings Report Dividend Announcement Analyst Forecast
VRTX Vertex Pharmaceuticals	4.3713 of 5 stars	$425.00 -0.6%	$555.17 +30.6%	+1.1%	$108.54B	$12.00B	25.21	6,400	Earnings Report Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BMY) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Which has more risk and volatility, AMGN or BMY?

Which has stronger valuation and earnings, AMGN or BMY?

Do insiders and institutionals hold more shares of AMGN or BMY?

Do analysts rate AMGN or BMY?

Is AMGN or BMY a better dividend stock?

Is AMGN or BMY more profitable?

Does the media prefer AMGN or BMY?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Do analysts rate BMY or EXEL?

Does the media refer more to BMY or EXEL?

Is BMY or EXEL more profitable?

Which has more volatility & risk, BMY or EXEL?

Which has preferable valuation & earnings, BMY or EXEL?

Do insiders and institutionals have more ownership in BMY or EXEL?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Do insiders & institutionals believe in BMY or GILD?

Which has more volatility and risk, BMY or GILD?

Does the media favor BMY or GILD?

Is BMY or GILD a better dividend stock?

Do analysts rate BMY or GILD?

Which has higher valuation & earnings, BMY or GILD?

Is BMY or GILD more profitable?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Do institutionals and insiders hold more shares of BMY or VRTX?

Which has more risk and volatility, BMY or VRTX?

Does the media prefer BMY or VRTX?

Do analysts prefer BMY or VRTX?

Which has higher valuation & earnings, BMY or VRTX?

Is BMY or VRTX more profitable?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Does the media prefer BMY or ABBV?

Which has higher earnings and valuation, BMY or ABBV?

Is BMY or ABBV more profitable?

Which has more volatility & risk, BMY or ABBV?

Do analysts prefer BMY or ABBV?

Do insiders and institutionals hold more shares of BMY or ABBV?

Is BMY or ABBV a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools